FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216645551> ?p ?o ?g. }

• W3216645551 endingPage "179" @default.
• W3216645551 startingPage "179" @default.
• W3216645551 abstract "With the evidence of waning immunity of the mRNA vaccine BNT162b2 (Pfizer-BioNTech), a nationwide third-dose (booster) vaccination campaign was initiated in Israel during August 2021; other countries have begun to administer a booster shot as well.To evaluate the initial short-term additional benefit of a 3-dose vs a 2-dose regimen against infection of SARS-CoV-2.This preliminary retrospective case-control study used 2 complementary approaches: a test-negative design and a matched case-control design. Participants were included from the national centralized database of Maccabi Healthcare Services, an Israeli healthcare maintenance organization covering 2.5 million members. Data were collected between March 1, 2020, and October 4, 2021, and analyses focused on the period from August 1, 2021, to October 4, 2021, because the booster dose was widely administered from August 1 onward.Either 2 doses or 3 doses of the BNT162b2 vaccine.The reduction in the odds of a positive SARS-CoV-2 polymerase chain reaction (PCR) test at different time intervals following receipt of the booster dose (0-6, 7-13, 14-20, 21-27, and 28-65 days) compared with receiving only 2 doses.The study population included 306 710 members of Maccabi Healthcare Services who were 40 years and older (55% female) and received either 2 or 3 doses of the BNT162b2 vaccine and did not have a positive PCR test result for SARS-CoV-2 prior to the start of the follow-up period. During this period, there were 500 232 PCR tests performed, 227 380 among those who received 2 doses and 272 852 among those who received 3 doses, with 14 989 (6.6%) and 4941 (1.8%) positive test results in each group, respectively. Comparing those who received a booster and those who received 2 doses, there was an estimated odds ratio of 0.14 (95% CI, 0.13-0.15) 28 to 65 days following receipt of the booster (86% reduction in the odds of testing positive for SARS-CoV-2).Previous studies have demonstrated that vaccine-derived protection against SARS-CoV-2 wanes over time. In this case-control analysis, we showed an association between receipt of the booster dose and a reduction in the odds of testing positive for SARS-CoV-2, potentially counteracting waning immunity in the short term. Further monitoring of data from this population is needed to determine the duration of immunity following the booster." @default.
• W3216645551 created "2021-12-06" @default.
• W3216645551 creator A5013907456 @default.
• W3216645551 creator A5022127687 @default.
• W3216645551 creator A5034265331 @default.
• W3216645551 creator A5068973184 @default.
• W3216645551 creator A5076126189 @default.
• W3216645551 creator A5090120637 @default.
• W3216645551 date "2022-02-01" @default.
• W3216645551 modified "2023-10-06" @default.
• W3216645551 title "Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine" @default.
• W3216645551 cites W1775522749 @default.
• W3216645551 cites W1963641435 @default.
• W3216645551 cites W1981055539 @default.
• W3216645551 cites W2162124703 @default.
• W3216645551 cites W2170034816 @default.
• W3216645551 cites W2790997422 @default.
• W3216645551 cites W2968409833 @default.
• W3216645551 cites W3092643927 @default.
• W3216645551 cites W3093667122 @default.
• W3216645551 cites W3111255098 @default.
• W3216645551 cites W3123366914 @default.
• W3216645551 cites W3131688063 @default.
• W3216645551 cites W3161135492 @default.
• W3216645551 cites W3162622073 @default.
• W3216645551 cites W3176897911 @default.
• W3216645551 cites W3180511106 @default.
• W3216645551 cites W3191894059 @default.
• W3216645551 cites W3201177512 @default.
• W3216645551 cites W3209833474 @default.
• W3216645551 cites W3214669231 @default.
• W3216645551 cites W4205483821 @default.
• W3216645551 doi "https://doi.org/10.1001/jamainternmed.2021.7382" @default.
• W3216645551 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34846533" @default.
• W3216645551 hasPublicationYear "2022" @default.
• W3216645551 type Work @default.
• W3216645551 sameAs 3216645551 @default.
• W3216645551 citedByCount "112" @default.
• W3216645551 countsByYear W32166455512021 @default.
• W3216645551 countsByYear W32166455512022 @default.
• W3216645551 countsByYear W32166455512023 @default.
• W3216645551 crossrefType "journal-article" @default.
• W3216645551 hasAuthorship W3216645551A5013907456 @default.
• W3216645551 hasAuthorship W3216645551A5022127687 @default.
• W3216645551 hasAuthorship W3216645551A5034265331 @default.
• W3216645551 hasAuthorship W3216645551A5068973184 @default.
• W3216645551 hasAuthorship W3216645551A5076126189 @default.
• W3216645551 hasAuthorship W3216645551A5090120637 @default.
• W3216645551 hasBestOaLocation W32166455511 @default.
• W3216645551 hasConcept C121332964 @default.
• W3216645551 hasConcept C12590561 @default.
• W3216645551 hasConcept C126322002 @default.
• W3216645551 hasConcept C1276947 @default.
• W3216645551 hasConcept C136764020 @default.
• W3216645551 hasConcept C143095724 @default.
• W3216645551 hasConcept C151956035 @default.
• W3216645551 hasConcept C156957248 @default.
• W3216645551 hasConcept C159654299 @default.
• W3216645551 hasConcept C160735492 @default.
• W3216645551 hasConcept C162324750 @default.
• W3216645551 hasConcept C187212893 @default.
• W3216645551 hasConcept C203014093 @default.
• W3216645551 hasConcept C203165030 @default.
• W3216645551 hasConcept C22070199 @default.
• W3216645551 hasConcept C2778979077 @default.
• W3216645551 hasConcept C2781413609 @default.
• W3216645551 hasConcept C2908647359 @default.
• W3216645551 hasConcept C32611913 @default.
• W3216645551 hasConcept C41008148 @default.
• W3216645551 hasConcept C50522688 @default.
• W3216645551 hasConcept C512399662 @default.
• W3216645551 hasConcept C71924100 @default.
• W3216645551 hasConcept C99454951 @default.
• W3216645551 hasConceptScore W3216645551C121332964 @default.
• W3216645551 hasConceptScore W3216645551C12590561 @default.
• W3216645551 hasConceptScore W3216645551C126322002 @default.
• W3216645551 hasConceptScore W3216645551C1276947 @default.
• W3216645551 hasConceptScore W3216645551C136764020 @default.
• W3216645551 hasConceptScore W3216645551C143095724 @default.
• W3216645551 hasConceptScore W3216645551C151956035 @default.
• W3216645551 hasConceptScore W3216645551C156957248 @default.
• W3216645551 hasConceptScore W3216645551C159654299 @default.
• W3216645551 hasConceptScore W3216645551C160735492 @default.
• W3216645551 hasConceptScore W3216645551C162324750 @default.
• W3216645551 hasConceptScore W3216645551C187212893 @default.
• W3216645551 hasConceptScore W3216645551C203014093 @default.
• W3216645551 hasConceptScore W3216645551C203165030 @default.
• W3216645551 hasConceptScore W3216645551C22070199 @default.
• W3216645551 hasConceptScore W3216645551C2778979077 @default.
• W3216645551 hasConceptScore W3216645551C2781413609 @default.
• W3216645551 hasConceptScore W3216645551C2908647359 @default.
• W3216645551 hasConceptScore W3216645551C32611913 @default.
• W3216645551 hasConceptScore W3216645551C41008148 @default.
• W3216645551 hasConceptScore W3216645551C50522688 @default.
• W3216645551 hasConceptScore W3216645551C512399662 @default.
• W3216645551 hasConceptScore W3216645551C71924100 @default.
• W3216645551 hasConceptScore W3216645551C99454951 @default.
• W3216645551 hasIssue "2" @default.

• next